Detalhe da pesquisa
1.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383908
2.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 378(14): 1277-1290, 2018 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562145
3.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer
; 126(18): 4156-4167, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32673417
4.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol
; 20(10): 1370-1385, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31427204
5.
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.
Jpn J Clin Oncol
; 47(7): 639-646, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28419248
6.
Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 379(1): 92-93, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29972749
7.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(7): 700-12, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24831977
8.
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
Breast Cancer Res Treat
; 139(2): 411-9, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23649189
9.
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.
J Immunother Cancer
; 10(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35304405
10.
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Eur Urol
; 81(3): 266-271, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750035
11.
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Clin Cancer Res
; 27(1): 78-86, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32873572
12.
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
Eur Urol
; 77(4): 449-453, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31732098
13.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
ESMO Open
; 5(6): e001079, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33246931
14.
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Clin Genitourin Cancer
; 18(6): 469-476.e4, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32641261
15.
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
Eur Urol
; 78(6): 822-830, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32811715
16.
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Clin Genitourin Cancer
; 18(6): 461-468.e3, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32718906
17.
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
J Immunother Cancer
; 8(2)2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32661118
18.
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
JAMA Oncol
; 5(10): 1411-1420, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31343665
19.
Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes.
J Clin Endocrinol Metab
; 93(5): 1893-900, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18319310
20.
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
J Clin Oncol
; 35(34): 3851-3858, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28678668